+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Hypercholesterolemia Drug Market by Mechanism of Action, Type of Disease, Drug Class - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5532796
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hypercholesterolemia Drug Market grew from USD 20.25 billion in 2023 to USD 21.43 billion in 2024. It is expected to continue growing at a CAGR of 6.32%, reaching USD 31.10 billion by 2030.

Hypercholesterolemia, commonly referred to as high cholesterol, is a prevalent condition characterized by elevated levels of cholesterol in the blood, necessitating therapeutic interventions to mitigate associated cardiovascular risks. The necessity for hypercholesterolemia drugs is underscored by the rising prevalence of the condition, influenced by aging populations, sedentary lifestyles, and dietary habits. These drugs are critical in managing and reducing low-density lipoprotein (LDL) cholesterol, thereby lowering the risk of heart disease and stroke. End-use applications span across hospitals, clinics, and home care, with increased dependency on prescription medications and supplements. Key growth factors influencing the hypercholesterolemia drug market include advancements in biopharmaceuticals, growing awareness of cardiovascular diseases, and the development of novel drug therapies like PCSK9 inhibitors. However, a notable opportunity lies in the expansion of generic medications as patents for major drugs expire, expected to make treatments more accessible on a global scale. Additionally, increasing investments in R&D for drug development focusing on personalized medicine could substantively enhance market opportunities. Despite these prospects, challenges such as stringent regulatory frameworks, potential side effects of medications, and significant competition from alternative therapies, such as dietary supplements, present limitations to market growth. Innovations in this domain could center around the development of more effective, minimally invasive drug delivery systems and further exploration of genetic and phenotypic factors in hypercholesterolemia for more targeted therapies. The hypercholesterolemia drug market is highly competitive and dynamic, characterized by rapid technological advancements and strategic partnerships aimed at enhancing product offerings. Businesses venturing into this market can leverage the opportunity by focusing on cost-effective production, strategic parenteral collaborations, and educating healthcare providers and patients about the benefits of treatment compliance and emerging alternatives, thereby aligning with public health goals and ensuring sustained market engagement.

Understanding Market Dynamics in the Hypercholesterolemia Drug Market

The Hypercholesterolemia Drug Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing incidence of heart disorders worldwide
    • Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
    • Increasing consumer healthcare spending and infrastructure spending by private and public organizations
  • Market Restraints
    • Availability of alternative substitutes in the market
    • Consumer awareness on healthy and fit diet
  • Market Opportunities
    • Technological advancements in introduction of novel drugs
    • Rising utilization of combination therapies across regions
  • Market Challenges
    • Competition from generic versions of branded drugs

Exploring Porter’s Five Forces for the Hypercholesterolemia Drug Market

Porter’s Five Forces framework further strengthens the insights of the Hypercholesterolemia Drug Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Hypercholesterolemia Drug Market

External macro-environmental factors deeply influence the performance of the Hypercholesterolemia Drug Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Hypercholesterolemia Drug Market

The Hypercholesterolemia Drug Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Hypercholesterolemia Drug Market

The Hypercholesterolemia Drug Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Hypercholesterolemia Drug Market

The Hypercholesterolemia Drug Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hypercholesterolemia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., AstraZeneca PLC, AtheroNova Inc., Aurobindo Pharma Limited, Cipla Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, Esperion Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals Inc., Mylan N.V., Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Hypercholesterolemia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Mechanism of Action
    • Bile Acid Sequestrants
    • Fibric Acid Derivatives
    • HMG-CoA Reductase Inhibitors
    • Nicotinic Acid
  • Type of Disease
    • Familial hypercholesterolemia (FH)
    • Non-Familial hypercholesterolemia (FH)
  • Drug Class
    • Non-Statins
    • Statins
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of heart disorders worldwide
5.1.1.2. Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
5.1.1.3. Increasing consumer healthcare spending and infrastructure spending by private and public organizations
5.1.2. Restraints
5.1.2.1. Availability of alternative substitutes in the market
5.1.2.2. Consumer awareness on healthy and fit diet
5.1.3. Opportunities
5.1.3.1. Technological advancements in introduction of novel drugs
5.1.3.2. Rising utilization of combination therapies across regions
5.1.4. Challenges
5.1.4.1. Competition from generic versions of branded drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Hypercholesterolemia Drug Market, by Mechanism of Action
6.1. Introduction
6.2. Bile Acid Sequestrants
6.3. Fibric Acid Derivatives
6.4. HMG-CoA Reductase Inhibitors
6.5. Nicotinic Acid
7. Hypercholesterolemia Drug Market, by Type of Disease
7.1. Introduction
7.2. Familial hypercholesterolemia (FH)
7.3. Non-Familial hypercholesterolemia (FH)
8. Hypercholesterolemia Drug Market, by Drug Class
8.1. Introduction
8.2. Non-Statins
8.3. Statins
9. Americas Hypercholesterolemia Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Hypercholesterolemia Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Hypercholesterolemia Drug Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH PROCESS
FIGURE 2. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 7. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. HYPERCHOLESTEROLEMIA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. HYPERCHOLESTEROLEMIA DRUG MARKET DYNAMICS
TABLE 7. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FIBRIC ACID DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NICOTINIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 29. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 30. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 32. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 46. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 47. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 50. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 55. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 92. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 102. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 110. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 113. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 114. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 116. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 117. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 137. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Hypercholesterolemia Drug Market, which are profiled in this report, include:
  • Abbvie Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • AtheroNova Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information